HIV-1 tat Protein (1-9) peptide

HIV-1 tat Protein (1-9) peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

MDPVDPNIE

Met-Asp-Pro-Val-Asp-Pro-Asn-Ile-Glu

9

95.8%

C₄₃H₁₆₈N₁₀O₁₇S

1029.14

Synthetic

Powder

Tat(l-9) is a short nonapeptide that is derived from the transactivator protein Tat of the human immunodeficiency virus-1 (HIV-1). It has been found to inhibit the activity of dipeptidyl peptidase IV (DP IV), which is a T cell activation marker. Tat(l-9) has also been shown to suppress the DNA synthesis of tetanus toxoid-stimulated peripheral blood mononuclear cells (PBMC). The paper discusses the effects of amino acid exchanges in the first three positions of Tat(l-9) and their influence on DP IV activity and PBMC proliferation.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Wrenger, S. et al. (2002). Effects of Nonapeptides Derived From the N-terminal Structure of Human Immunodeficiency Virus-1 (HIV-1) Tat on Suppression of CD26-Dependent T Cell Growth. In: Langner, J., Ansorge, S. (eds) Cellular Peptidases in Immune Functions and Diseases 2. Advances in Experimental Medicine and Biology, vol 477. Springer, Boston, MA. https://doi.org/10.1007/0-306-46826-3_18

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.